Abstract: A machining time-estimating method for a wire electrical discharge machine for estimating the remaining machining time (Tr) during the machining of a workpiece comprises: a step for setting a predicted machining velocity; a step for determining the actual machining velocity; a step for determining an estimated machining velocity so as to incorporate the predicted machining velocity and the actual machining velocity at a specified ratio, that is, a reference ratio; and a step for calculating remaining machining time from the estimated machining velocity. By executing the actual machining velocity-determining step to the remaining machining time-calculating step repeatedly to estimate remaining machining time moment by moment, remaining wire electrical discharge machining time is estimated with reduced error.

Abstract: A machining time-estimating method for a wire electrical discharge machine for estimating the remaining machining time (Tr) during the machining of a workpiece comprises: a step for setting a predicted machining velocity; a step for determining the actual machining velocity; a step for determining an estimated machining velocity so as to incorporate the predicted machining velocity and the actual machining velocity at a specified ratio, that is, a reference ratio; and a step for calculating remaining machining time from the estimated machining velocity. By executing the actual machining velocity-determining step to the remaining machining time-calculating step repeatedly to estimate remaining machining time moment by moment, remaining wire electrical discharge machining time is estimated with reduced error.

Abstract: Provided is a pyrimidine nucleoside compound represented by the following formula (1): or a pharmaceutically acceptable salt thereof, wherein one of X and Y represents a cyano group, and the other represents a hydrogen atom; one of R1 and R2 represents a hydrogen atom, a carbonyl group having a C1-C6 alkyl group which has been mono-substituted by an amino group, or a group represented by (R3)(R4)(R5)Si—, and the other represents a group represented by (R6)(R7)(R8)Si—, or R1 and R2 together form a 6-membered cyclic group represented by —Si(R9)(R10)—; R3, R4, R5, R6, R7, and R8 each represent a C1-C10 linear or branched alkyl group which may have a substituent, a C3-C6 cycloalkyl group which may have a substituent, a C6-C14 aryl group which may have a substituent, or a C1-C6 alkyl group which has been substituted by one or two C6-C14 aryl groups and which may have a substituent; and R9 and R10 each represent a C1-C6 linear or branched alkyl group which may have a substituent.

Abstract: A novel pyrimidine nucleoside compound represented by the following formula (1): (wherein one of X and Y represents a cyano group, and the other represents a hydrogen atom; one of R1 and R2 represents a hydrogen atom, a carbonyl group having a C1-C6 alkyl group which has been mono-substituted by an amino group, or a group represented by (R3)(R4)(R5)Si—, and the other represents a silyl group represented by (R6)(R7)(R8)Si—, or R1 and R2 together form a 6-membered cyclic group represented by —Si (R9)(R10)—; R3, R4, R5, R6, R7, and R8 each represent an alkyl group, a cyclic alkyl group, an aryl group, or an alkyl group which has been substituted by one or two aryl groups; and R9 and R10 each represent an alkyl group) or a salt thereof. The novel pyrimidine nucleoside compound exhibits excellent anti-tumor effect as compared with existing pyrimidine nucleoside compounds.